New hope for pancreatic cancer: drug combo shows promise in early trial

NCT ID NCT04888312

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 23 times

Summary

This study tests a new drug called mitazalimab combined with standard chemotherapy in people with metastatic pancreatic cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 94 adults who have not had prior chemotherapy for this cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut-Lévêque,

    Bordeaux, France

  • Centre Lyon Berard

    Lyon, France

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • Hopital Européen Georges Pompidou

    Paris, 75015, France

  • Hospital Erasme

    Brussels, Belgium

  • Hospital Universitario La Paz, Madrid, Spain

    Madrid, Spain

  • Hospital Universitario Miguel Servet, Zaragoza, Spain

    Zaragoza, Spain

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

    Madrid, Spain

  • Hospital Universitario Vall d'Hebron, Barcelona, Spain

    Barcelona, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

    Seville, Spain

  • Institut Paoli-Calmettes

    Marseille, France

  • Institute de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France

  • UZA Antwerp

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, 9000, Belgium

Conditions

Explore the condition pages connected to this study.